The use of MEKi as a frontline strategy is justifiable in patients with ECD; however, clinicians must bear in mind that some cases may not be driven by MAPK-ERK pathway mutations and hence may not respond to MEK-inhibition and may need alternate treatments. This evidence concerns the gene MAP2K7 and familial atrioventricular septal defect.